Bronchiolitis

Pediatric Critical Care Medicine

Volumn 2, Issue , 2014, Pages 75-85

  Thorburn, Kentigern ^a   McNamara, Paul Stephen ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Bronchiolitis; Co morbidity; Respiratory syncytial virus (RSV)

Indexed keywords

EID: 84929044780     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4471-6356-5_5     Document Type: Chapter

References (81)

1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360:588-98.
2. Buckingham SC, Quasney MW, Bush AJ, Devincenzo JP. Respiratory syncytial virus infections in the pediatric intensive care unit: clinical characteristics and risk factors for adverse outcomes. Pediatr Crit Care Med. 2001;2:318-23.
3. Smyth RL, Openshaw PJ. Bronchiolitis. Lancet. 2006;368:312-22.
4. Adams JM. Primary virus pneumonitis with cytoplasmic inclusion bodies: a study of an epidemic involving thirty-two infants with nine deaths. J Am Med Assoc. 1941;116:925-33.
5. Chanock RM, Parrott RH, Vargosko AJ, et al. Acute respiratory diseases of viral etiology. IV. Respiratory syncytial virus. Am J Public Health Nations Health. 1962;52:918-25.
6. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917-28.
7. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545-55.
8. Openshaw PJ. Antiviral immune responses and lung inflammation after respiratory syncytial virus infection. Proc Am Thorac Soc. 2005;2:121-5.
9. Openshaw PJ, Tregoning J, Harker J. RSV 2005: global impact, changing concepts, and new challenges. Viral Immunol. 2005;18:749-51.
10. Welliver TP, Garofalo RP, Hosakote Y, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis. 2007;195:1126-36.
11. McNamara PS, Flanagan BF, Selby AM, et al. Pro-and antiinflammatory responses in respiratory syncytial virus bronchiolitis. Eur Respir J. 2004;23:106-12.
12. McNamara PS, Flanagan BF, Hart CA, Smyth RL. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis. 2005;191:1225-32.
13. Bezerra PG, Britto MC, Correia JB, et al. Viral and atypical bacterial detection in acute respiratory infection in children underfive years. PLoS One. 2011;6:e18928.
14. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr. 2003;143:S112-7.
15. Handforth J, Friedland JS, Sharland M. Basic epidemiology and immunopathology of RSV in children. Paediatr Respir Rev. 2000;1:210-4.
16. Argent AC. Through the mists of treatment: managing severe bronchiolitis. Pediatr Crit Care Med. 2008;9:659-61.
17. Peret TC, Hall CB, Hammond GW, et al. Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis. 2000;181:1891-6.
18. Kneyber MC, Plötz FB. Respiratory syncytial virus (RSV) in the pediatric intensive care. In: Vincent J-L, editor. Intensive care medicine annual update 2007. New York: Springer; 2007. p. 145-56.
19. Thorburn K, Harigopal S, Reddy V, et al. High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis. Thorax. 2006;61:611-5.
20. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-86.
21. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child. 2009;94:99-103.
22. Mallory MD, Shay DK, Garrett J, Bordley WC. Bronchiolitis management preferences and the influence of pulse oximetry and respiratory rate on the decision to admit. Pediatrics. 2003;111:e45-51.
23. Bordley WC, Viswanathan M, King VJ, et al. Diagnosis and testing in bronchiolitis: a systematic review. Arch Pediatr Adolesc Med. 2004;158:119-26.
24. American Academy of Pediatrics. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118:1774-93.
25. Friis B, Eiken M, Hornsleth A, Jensen A. Chest X-ray appearances in pneumonia and bronchiolitis. Correlation to virological diagnosis and secretory bacterialfindings. Acta Paediatr Scand. 1990;79:219-25.
26. Elphick HE, Lancaster GA, Solis A, et al. Validity and reliability of acoustic analysis of respiratory sounds in infants. Arch Dis Child. 2004;89:1059-63.
27. Frankel LR, Derish M. Respiratory syncytial virus induced respiratory failure in the pediatric patient. New Horiz. 1999;7:335-46.
28. Hammer J, Numa A, Newth CJ. Acute respiratory distress syndrome caused by respiratory syncytial virus. Pediatr Pulmonol. 1997;23:176-83.
29. Tasker RC, Gordon I, K K. Time course of severe respiratory syncytial virus infection in mechanically ventilated infants. Acta Paediatr. 2000;89:938-41.
30. Baumer JH. SIGN guideline on bronchiolitis in infants. Arch Dis Child Educ Pract Ed. 2007;92:ep149-51.
31. Fitzgerald DA, Kilham HA. Bronchiolitis: assessment and evidence-based management. Med J Aust. 2004;180:399-404.
32. Plint AC, Johnson W, Wiebe N, et al. Practice variation among pediatric emergency departments in the treatment of bronchiolitis. Acad Emerg Med. 2004;11:353-60.
33. Carraro S, Zanconato S, Baraldi E. Bronchiolitis: from empiricism to scientific evidence. Minerva Pediatr. 2009;61:217-25.
34. Lahti M, Lofgren L, Marttila R, et al. Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection. Pediatr Res. 2002;51:696-9.
35. McNamara PS, Flanagan BF, Smyth RL, Hart CA. Impact of human metapneumovirus and respiratory syncytial virus co-infection in severe bronchiolitis. Pediatr Pulmonol. 2007;42:740-3.
36. Richard N, Komurian-Pradel F, Javouhey E, et al. The impact of dual viral infection in infants admitted to a pediatric intensive care unit associated with severe bronchiolitis. Pediatr Infect Dis J. 2008;27:213-7.
37. van Woensel JB, Lutter R, Biezeveld MH, et al. Effect of dexamethasone on tracheal viral load and interleukin-8 tracheal concentration in children with respiratory syncytial virus infection. Pediatr Infect Dis J. 2003;22:721-6.
38. Devincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis. 2005;191:1861-8.
39. Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection-a systematic review. Crit Care. 2006;10:R107.
40. Eisenhut M, Sidaras D, Johnson R, Thorburn K. Cardiac Troponin T levels and myocardial involvement in children with severe respiratory syncytial virus lung disease. Acta Paediatr. 2004;93:887-90.
41. Thorburn K, Eisenhut M, Shauq A, Burgess M. Right ventricular function in children with severe respiratory syncytial virus (RSV) bronchiolitis. Minerva Anestesiol. 2011;77:46-53.
42. Eisenhut M, Thorburn K, Ahmed T. Transaminase levels in ventilated children with respiratory syncytial virus bronchiolitis. Intensive Care Med. 2004;30:931-4.
43. Kho N, Kerrigan JF, Tong T, Knilans J. Respiratory syncytial virus infection and neurologic abnormalities: retrospective cohort study. J Child Neurol. 2004;19:859-64.
44. Ralston S, Hill V. Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatr. 2009;155:728-33.
45. Reynolds EO, Cook CD. The treatment of bronchiolitis. J Pediatr. 1963;63:1205-7.
46. Rojas MX, Granados RC, Charry-Anzola LP. Oxygen therapy for lower respiratory tract infections in children between 3 months and 15 years of age. Cochrane Database Syst Rev. 2009;1, CD005975.
47. Gadomski AM, Brower M. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2010;12, CD001266.
48. Levin DA, Garg A, Hall LJ, et al. A prospective randomized controlled blinded study of three bronchodilators in infants with respiratory syncytial virus bronchiolitis on mechanical ventilation. Pediatr Crit Care Med. 2008;9:598-604.
49. Hartling L, Wiebe N, Russell K, Klassen TP. Epinephrine for bronchiolitis. Cochrane Database Syst Rev. 2004;1, CD003123.
50. Plint AC, Johnson DW, Patel H, et al. Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med. 2009;360:2079-89.
51. Fernandes RM, Bialy LM, Vandermeer B, et al. Glucocorticoids for acute viral bronchiolitis in infants and children. Cochrane Database Syst Rev. 2010;10, CD004878.
52. Van Woensel JB, Vyas H, STAR Trail Group. Dexamethasone in children mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus: a randomized controlled trial. Crit Care Med. 2011;39:1779-83.
53. Davison C, Ventre KM, Luchetti M, Randolph AG. Efficacy of interventions for bronchiolitis in critically ill infants: a systematic review and meta-analysis. Pediatr Crit Care Med. 2004;5:482-9.
54. Ramesh P, Samuels M. Are methylxanthines effective in preventing or reducing apnoeic spells in infants with bronchiolitis? Arch Dis Child. 2005;90:321-2.
55. Pediatric emergency center Al-Sadd, Hamad Medical Corporation, Doha, Qatar; Caffeine citrate for the treatment of apnea associated with bronchiolitis in young infants. 2011. http://clinicaltrials.gov/ show/NCT01435486 . Accessed 20 Aug 2012.
56. Perrotta C, Ortiz Z, Roque M. Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. Cochrane Database Syst Rev. 2007;1, CD004873.
57. Mandelberg A, Amirav I. Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale. Pediatr Pulmonol. 2010;45:36-40.
58. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2008;4, CD006458.
59. Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev. 2007;1, CD000181.
60. Levin D, Tribuzio M, Green-Wrzesinki T, et al. Empiric antibiotics are justified for infants with respiratory syncytial virus lower tract infection presenting with respiratory failure: a prospective study and evidence review. Pediatr Crit Care Med. 2010;11:390-5.
61. Thorburn K, Shetty N, Darbyshire AP. Concomitant bacterial pneumonia and empirical antibiotics in severe respiratory syncytial virus infection. Pediatr Crit Care Med. 2011;12:119.
62. Ventre K, Haroon M, Davison C. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database Syst Rev. 2006;3, CD005150.
63. Liet JM, Ducruet T, Gupta V, Cambonie G. Heliox inhalation therapy for bronchiolitis in infants. Cochrane Database Syst Rev. 2010;2010, CD006915.
64. Patel NR, Hammer J, Nichani S, Newth CJ. Effect of inhaled nitric oxide on respiratory mechanics in ventilated infants with RSV bronchiolitis. Intensive Care Med. 1999;251:81-7.
65. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxemic respiratory failure in children and adults. Cochrane Database Syst Rev. 2003;1, CD002787.
66. Nasr SZ, Strouse PJ, Soskolne E, et al. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest. 2001;120:203-8.
67. Boogaard R, Hulsmann AR, Veen L, et al. Recombinant human deoxyribonuclease in infants with respiratory syncytial virus bronchiolitis. Chest. 2007;131:788-95.
68. Larrar S, Essouri S, Durand P, et al. Effects of nasal continuous positive airway pressure ventilation in infants with severe acute bronchiolitis. Arch Pediatr. 2006;13:1397-403.
69. Thia LP, McKenzie SA, Blyth TP, et al. Randomised controlled trial of nasal continuous positive airways pressure (CPAP) in bronchiolitis. Arch Dis Child. 2008;93:45-7.
70. Shah PS, Ohlsson A, Shah JP. Continuous negative extrathoracic pressure or continuous positive airway pressure for acute hypoxemic respiratory failure in children. Cochrane Database Syst Rev. 2008;1, CD003699.
71. McKiernan C, Chua LC, Visintainer PF, Allen H. Highflow nasal cannulae therapy in infants with bronchiolitis. J Pediatr. 2010;156:634-8.
72. Lebel MH, Gauthier M, Lacroix J, Buithieu M. Respiratory failure and mechanical ventilation in severe bronchiolitis. Arch Dis Child. 1989;64:1431-7.
73. Flamant C, Hallalel F, Nolent P, Renolleau S. Severe respiratory syncytial virus bronchiolitis in children: from short mechanical ventilation to extracorporeal membrane oxygenation. Eur J Pediatr. 2005;164:93-8.
74. Khan JY, Kerr SJ, Tometzki A, et al. Role of ECMO in the treatment of respiratory syncytial virus bronchiolitis: a collaborative report. Arch Dis Child Fetal Neonatal Ed. 1995;73:F91-4.
75. Steinhorn RH, Green TP. Use of extracorporeal membrane oxygenation in the treatment of respiratory syncytial virus bronchiolitis: the national experience, 1983 to 1988. J Pediatr. 1990;116:338-42.
76. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102:531-7.
77. Fuller H, Del MC. Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev. 2006;4, CD004883.
78. American Academy of Pediatrics-Committee on Infectious Diseases. Policy statement-modified recommendations for the use of palivizumab for the prevention of respiratory syncytial virus infections. Pediatrics. 2009;124:1774-93.
79. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532-40.
80. Prais D, Danino D, Schonfeld T, Amir J. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey. Chest. 2005;128:2765-71.
81. Olszewska W, Ispas G, Schnoeller C, et al. Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J. 2011;38:401-8.